Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Veracyte's Other Non Operating Income fell 18397.85% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 5931.42%. This contributed to the annual value of $9.6 million for FY2024, which is 456.28% up from last year.
  • According to the latest figures from Q3 2025, Veracyte's Other Non Operating Income is -$4.1 million, which was down 18397.85% from $6.5 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's Other Non Operating Income ranged from a high of $6.5 million in Q2 2025 and a low of -$4.1 million during Q3 2025
  • Its 5-year average for Other Non Operating Income is $1.6 million, with a median of $1.2 million in 2021.
  • Data for Veracyte's Other Non Operating Income shows a peak YoY increase of 352857.14% (in 2021) and a maximum YoY decrease of 198571.43% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Veracyte's Other Non Operating Income stood at $1.0 million in 2021, then soared by 94.78% to $2.0 million in 2022, then surged by 154.42% to $5.0 million in 2023, then tumbled by 114.54% to -$732000.0 in 2024, then tumbled by 454.23% to -$4.1 million in 2025.
  • Its Other Non Operating Income was -$4.1 million in Q3 2025, compared to $6.5 million in Q2 2025 and $4.5 million in Q1 2025.